{"nct_id":"NCT04165096","title":"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)","status":"COMPLETED","status_verified_date":"2025-06","start_date":"2020-01-21","start_date_type":"ACTUAL","primary_completion_date":"2025-04-30","primary_completion_date_type":"ACTUAL","completion_date":"2025-05-28","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}